The Ophthalmology Times Group talked to an optometrist practice about their experience with ocular nutraceuticals
Don’t miss our editorial advisory board members at the Floretina/ICOOR meeting
EAB members from Ophthalmology Times Europe, Ophthalmology Times and Modern Retina are presenting in Florence
PHOTON Results and Their Relation to DME Patients in Your Practice
John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.
The Floretina ICOOR meeting begins in Florence, Italy
What to expect from 4 days in the Fortezza de Basso
PULSAR Results and Their Relation to nAMD Patients in Your Practice
John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.
Arctic Vision partners with Santen Pharmaceutical Co., Ltd. to commercialise ARVN001 in China
ARVN001 is indicated for the treatment of uveitic macular oedema and certain other ophthalmic indications
European Commission approves aflibercept biosimilar OPUVIZ (previously SB15) from Samsung Bioepis
OPUVIZ, previously known as the biosimilar candidate SB15, has been approved for the treatment of nAMD, DME and other retinal diseases